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Abstract 
The lysine‑specific histone demethylase 1A (KDM1A) was the first demethylase to challenge the concept of the 
irreversible nature of methylation marks. KDM1A, containing a flavin adenine dinucleotide (FAD)‑dependent amine 
oxidase domain, demethylates histone 3 lysine 4 and histone 3 lysine 9 (H3K4me1/2 and H3K9me1/2). It has emerged 
as an epigenetic developmental regulator and was shown to be involved in carcinogenesis. The functional diversity of 
KDM1A originates from its complex structure and interactions with transcription factors, promoters, enhancers, onco‑
proteins, and tumor‑associated genes (tumor suppressors and activators). In this review, we discuss the microenviron‑
ment of KDM1A in cancer progression that enables this protein to activate or repress target gene expression, thus 
making it an important epigenetic modifier that regulates the growth and differentiation potential of cells. A detailed 
analysis of the mechanisms underlying the interactions between KDM1A and the associated complexes will help to 
improve our understanding of epigenetic regulation, which may enable the discovery of more effective anticancer 
drugs.
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Background
Epigenetic modifications are crucial for physiological 
development and steady-state gene expression in eukary-
otes [1] and are required for various biological processes 
ranging from gene expression to disease pathogenesis 
[2]. DNA methylation, histone modifications, and post-
translational modifications (PTMs) represent epigenetic 
alterations that may, alone or in combination, modify 
chromatin structure and gene activity by facilitating 
either gene activation or repression depending on the 
regulator type [3]. Histone methylation is the most versa-
tile epigenetic modification involved in the establishment 
and maintenance of the epigenome [4]. The methylation 
of lysine residues at specific chromatin positions is essen-
tial for many processes, such as the activation and repres-
sion of transcription, transcriptional silencing mediated 
by heterochromatin, DNA repair, and inactivation of the 
X-chromosome, that are involved in the regulation of 
development. Additionally, these alterations may repre-
sent aberrant markers indicating the development of dif-
ferent types of cancer and other diseases [5–7].
Lysine residues can be mono-, di-, and tri-methylated 
in the nucleosome at strategic chromatin positions, and 
these methylated states have different functions [8]. 
Lysine no. 4, 9, 27, 36, and 79 of histone H3 and lysine 
20 of histone H4 are the most frequently studied histone 
methylation sites and are associated with various biologi-
cally significant processes [9]. These methylation marks 
were considered stable and irreversible prior to the dis-
covery of the molecules termed “erasers,” i.e., histone 
demethylases [10]. Shi et  al. made the first discovery of 
histone lysine demethylase in 2004 [11], and this led to 
the establishment of new paradigms in the field of epi-
genetics (Fig.  1). These epigenetic regulators have been 
clustered into two subclasses [12]: one, including the 
majority of these regulators, containing a jumonji domain 
that depend on iron and oxoglutarate as cofactors [13], 
and the other comprising of two lysine-specific demethy-
lases that contain an amine oxidase domain and rely on 
flavin adenine dinucleotide (FAD) as their cofactor [14]. 
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All histone modifiers were shown to have important 
roles in gene regulation and epigenome establishment 
[15]. However, lysine-specific histone demethylase 1A 
(KDM1A/LSD1), being the first identified histone dem-
ethylase, has been widely explored, and numerous studies 
have described its biological roles [16]. KDM1A repre-
sents an important enzyme that plays significant roles in 
the regulation of embryonic development and differen-
tiation [17]. Furthermore, together with associated pro-
teins, this protein regulates many physiological processes 
involved in the shape and identity determination of stem 
and progenitor cells and also plays a role in their differen-
tiation into specialized cells, i.e., hematopoietic, neural, 
mesenchymal, sperm, and fat cells [18, 19]. KDM1A has 
also been associated with the development of a variety of 
pathological conditions, such as cancer, neuronal disor-
ders, and viral infections [20].
The functional diversity of KDM1A is supported by its 
complex structure [19]. In this review, we focus on the 
microenvironment of KDM1A in carcinogenesis and its 
structure, which is involved in the maintenance of its 
microenvironment by establishing complex interactions 
with a variety of transcriptional factors, promoters, acti-
vators, corepressors, and noncoding RNAs. Additionally, 
we discuss the versatile nature of KDM1A as an epige-
netic modifier, regulating the expression of a number 
of genes involved in epithelial–mesenchymal transition 
(EMT). Moreover, the potential and challenges associ-
ated with KDM1A therapeutic targeting are summarized 
here, together with a brief description of the similarities 
and differences between this demethylase and its recently 
discovered homolog, KDM1B, the other member of the 
FAD-dependent demethylase family.
Structural analysis of KDM1A
KDM1A, the first demethylase to be identified, is also 
known as LSD1, AOF2, BHC110, or KIAA0601 [21], and 
structural analyses have demonstrated that this protein 
contains an amine oxidase-like domain (AOL) [22]. Ini-
tially, KDM1A was considered a nuclear protein, similar 
to the FAD-dependent amine oxidases, but it was later 
shown to be a demethylase [23]. Despite the structural 
similarity between the AOL domain of KDM1A and 
the amine oxidase domains of other amine oxidases, it 
exhibits numerous differences, e.g., it contains a SWIRM 
(swi3p/Rsc8p/Moira) domain at its N-terminus, which 
plays a significant role in protein–protein interactions 
[24]. Furthermore, KDM1A contains a TOWER domain 
(90-residue insert), dividing the AOL domain into two 
subdomains (Fig.  2) [25, 26]. One subdomain of AOL 
interacts with the SWIRM domain, forming a core struc-
ture that binds FAD, while the other specifically binds 
the substrate [27]. The FAD-binding subdomain of AOL 
is similar to the amine oxidase domain of other amine 
oxidases, but the substrate-binding subdomain contains 
a large binding pocket with acidic features at its surface 
to facilitate the accommodation of long basic histone 
tails by maintaining specific interactions with the first 20 
amino acids of histone 3 (H3) [28]. Moreover, the active 
site of KDM1A possesses side chains at its rim that are 
negatively charged in order to establish interactions with 
the tail of the histone substrate through hydrogen bond-
ing and salt bridges [29]. This unique KDM1A binding 
site mediates its demethylation function and enables 
KDM1A to recognize a wide range of nonhistone sub-
strates [30–32].
The SWIRM domain of KDM1A does not bind with 
DNA molecules, as it is specific for protein–protein 
interactions and maintains the structural integrity of 
protein substrates [24, 27]. Furthermore, it is involved in 
altering the substrate specificity of KDM1A from H3K4 
to H3K9 [33, 34]. In addition to the different structural 
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Fig. 1 Epigenetic modifications and their biological roles. 
Epigenetic modifications are highly dynamic, and different types 
of modifications have been identified: DNA methylation, histone 
modifications, and microRNA‑mediated modifications. Histone 
modifications are extremely versatile, and proteins known as “writers,” 
“readers,” and “erasers” are involved in this process. The writers, such 
as histone methyltransferases (HMTs), histone acetyltransferases 
(HATs), and kinases, add specific marks on sequences of amino 
acids on histone tails. Readers, such as proteins containing a 
bromo‑domain, chromo‑domain, or tudor‑domain, are able to read 
these specific marks, which are further removed by the erasers, 
i.e., histone demethylases (KDMs), histone deacetylases (HDACs), 
and phosphatases. These histone modifiers, together with other 
epigenetic regulators, play an important role in the regulation of 
diverse biological functions [7]
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on the number of residues in the substrate-binding site 
and at the interface of the AOL-SWIRM domain [35, 
36]. Some of these residues affect the catalytic capacity 
of KDM1A, whereas others affect protein structure and 
substrate interactions [37]. KDM1A shows high substrate 
specificity, and mutations in substrates hinder the physi-
cal enzyme–substrate interactions, ultimately inhibiting 
target demethylation [31, 38]. Therefore, the demethyla-
tion capacity of KDM1A is affected by residual PTMs.
KDM1A can recognize p53, E2F1, and DNMT1, 
in addition to H3 [32, 39, 40], although no structural 
homology exists between histones and these nonhistone 
substrates [41]. It is possible that the unique structure of 
KDM1A and its microenvironment allows interactions 
with a wide range of substrates.
Comparison between KDM1A and KDM1B
KDM1B (also known as LSD2 or AOF1) represents the 
second FAD-dependent AOL-domain-containing dem-
ethylase belonging to the LSD family of histone demethy-
lases [21]. KDM1A and KDM1B share many structural 
properties, such as the presence of the catalytic AOL 
domain and SWIRM domain specific for chromatin 
and protein interactions. Unlike the SWIRM domain of 
KDM1A, the SWIRM domain of KDM1B is closely asso-
ciated with the AOL domain and is involved in maintain-
ing interactions with glyoxylate reductase 1 (GLYR1), a 
positive regulator of demethylation [42]. A coiled loop, 
unique to KDM1B and absent from the SWIRM domain 
of KDM1A, is involved in the establishment of this inter-
action [26].
Although KDM1A and KDM1B both contain the AOL 
and SWIRM domains, but the structure of these domains 
vary between these two homologs. KDM1A and KDM1B 
interact with different proteins and exhibit essentially dif-
ferent genomic profiles. The primary difference between 
these LSD family members is that KDM1A is involved 
in the formation of the RE1-silencing transcription fac-
tor (REST) corepressor (CoREST) complex through the 
TOWER domain that is absent in KDM1B [29, 35, 37]. 
Instead, KDM1B possesses a zinc finger domain at its 
amino terminus (Fig. 2) that is unique to KDM1B and is 
composed of two individual zinc fingers, i.e., an N-termi-
nal  C4H2C2-type zinc finger and a CW-type zinc finger 
[34, 43]. CW-type zinc finger domains are found in many 
chromatin remodeling protein complexes and have the 
ability to bind to methylated histone proteins [44–46]. 
In contrast to other CW-type zinc finger domains, how-
ever, the CW-type zinc finger domain of KDM1B does 
not bind to the methylated H3 tail [43]. This N-termi-
nal zinc finger domain is also required for the binding 
of FAD cofactor [43]. Moreover, in addition to its roles 
in protein–protein and DNA–protein interactions, the 
N-terminal zinc finger domain functions as a structural 
scaffold via intramolecular interactions [43]. While it is 
clear that the unique amino terminal zinc finger domain 
and SWIRM domain of KDM1B are crucial for the dem-
ethylase activity of this enzyme, their detailed mecha-
nisms of action are currently unknown [43]. From a 
functional point of view, KDM1B differs from KDM1A in 
its ability to demethylate both core histones and nucleo-
somal substrates [26].
Interacting partners of KDM1A, its substrate specificity, 
and functional diversity
KDM1A was initially identified as a binding partner of 
CoREST [37, 47]. KDM1A, together with CoREST, is fre-
quently found in many other larger protein complexes, 
in which it acts as a scaffold by joining the deacetylase 
and demethylase activities into a single complex [31, 38, 
48–50]. The association of KDM1A with the CoREST 
complex allows it to demethylate the nucleosome [51]. In 
Fig. 2 Structural domain analysis of KDM1A and KDM1B. Lysine‑specific demethylase 1A and 1B each contain an amine oxidase‑like domain and a 
SWIRM (SWI3, RSC8, and Moira) domain. The SWIRM domain of KDM1A is specific for chromatin–protein interactions, while that of KDM1B interacts 
with glyoxylate reductase 1 (GLYR1). KDM1A and 1B are characterized by TOWER and zinc finger (ZF) domains. The tower domain of KDM1A divides 
the AOL domain into two halves and is involved in interactions with different protein complexes [18]
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addition to CoREST, its paralogs, i.e., CoREST2 and CoR-
EST3, also bind to KDM1A and regulate the functional 
activities of this demethylase upon incorporation into 
larger protein complexes [52, 53]. However, CoREST2 
exhibits a decreased ability to facilitate KDM1A-medi-
ated nucleosome demethylation [52]. Unlike CoREST2, 
competitive inhibition of KDM1A-mediated nucleosomal 
demethylation is observed for CoREST3; thus, it exhibits 
even stronger antagonistic behavior [53]. The functional 
diversity of KDM1A depends on its interacting partners 
(Fig.  3), including protein complexes, transcription fac-
tors, receptors, noncoding RNAs, and nonhistone pro-
teins [31, 38, 54].
KDM1A interacts with orphan nuclear hormone 
receptor TLX and plays a role in the regulation of neu-
ronal cell differentiation [55]. TLX recruits the CoR-
EST/KDM1A/HDAC1 complex in KDM1A-dependent 
manner via direct interactions with the AOL and 
SWIRM domains of KDM1A to facilitate H3K4 dem-
ethylation and H3 deacetylation and to maintain other 
downstream genes in a repressed state [56]. The TLX/
KDM1A complex also regulates neuronal stem cell pro-
liferation [57]. The interaction of KDM1A with TLX 
aids in the timely regulation of neuronal proliferation 
and differentiation events [58].
The transcription factor TAL1 is involved in the regu-
lation of the normal processes of hematopoiesis and 
leukemogenesis and functions as an activator and repres-
sor of transcription [59]. These transcriptional repres-
sion and activation activities of TAL1 are maintained by 
its interactions with a variety of complexes and depend 
upon many other factors [60–64]. TAL1 acts as the bind-
ing partner of KDM1A in association with the CoR-
EST/HDAC complex and functions as a repressor of 
erythroid-specific genes in progenitor cells prior to dif-
ferentiation events [65]. During the early stages of dif-
ferentiation, the interaction of KDM1A and TAL1 is lost, 
and the repression of these erythroid-specific genes is 
eliminated. The PTM of TAL1 plays a role in its binding 































Fig. 3 KDM1A interacting partners and functional diversity. The microenvironment of KDM1A contains various protein complexes (e.g., CoREST, 
NuRD, and RCOR2), receptors (estrogen, androgen, and TLX), noncoding RNAs (HOTAIR, SRA and TERRAs), microRNAs (miR‑137 and miR‑329), 
nonhistone proteins (p53, E2F1, and DNMT1) and transcription factors (TLA and SNAIL). The interaction of KDM1A with these diverse factors 
allows the dynamic regulation of different biological processes through the suppression and the activation of target gene expression depending 
upon the type of its interacting partner, i.e., the interaction of KDM1A with miR‑137 downregulate the expression of KDM1A and in turn led to the 
differentiation of cells by activating the associated genes while its association with CoREST results in downregulation/suppression of target genes
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the dissociation of the KDM1A complex from TAL1 and 
mediates transcriptional activation [65, 66].
KDM1A also interacts with C-terminal binding pro-
teins (CtBP), which are well-known repressors of mam-
malian gene expression [67]. The interaction of KDM1A 
with CtBP was known before the discovery of its demeth-
ylase activity [50] and is implicated in a variety of CtBP 
functions, such as the regulation of pituitary gland devel-
opment [68], repression of the tumor-suppressor gene 
BRCA1 [69], and activation of tissue-specific genes in 
endocrine cells in the gastrointestinal tract [70, 71]. How-
ever, the more established role of the KDM1A and CtBP 
association is the suppression of E-cadherins, proteins 
involved in the process of EMT [50, 72, 73].
The interaction of KDM1A with the nucleosome 
remodeling and histone deacetylase (NuRD) complex 
implicates KDM1A in a variety of biological processes 
[74, 75], since NuRD regulates various biologically signif-
icant events, ranging from development to the progres-
sion of different types of malignancies [76]. By binding 
with the NuRD complex, KDM1A catalyzes the dem-
ethylation of nucleosome substrates [75]. Instead of the 
CoREST complex, MTA proteins that structurally resem-
ble CoREST recruit KDM1A and mediate the demeth-
ylation reaction of KDM1A [77]. KDM1A, in association 
with the NuRD complex, is involved in the repression of 
the TGF-β signaling pathway and the inhibition of EMT 
[75].
In addition to the aforementioned interactions of 
KDM1A, it also takes part in nuclear hormonal signal-
ing by interacting with androgen receptors (ARs) [78] 
and estrogen receptors (ERs). ARs are associated with the 
regulation of prostate function, from normal tissue devel-
opment to the initiation and progression of metastasis 
[79]. KDM1A, in association with ARs, changes its sub-
strate specificity from H3K4me2 to H3K9me1/2 (Fig. 4) 
[78]. This change facilitates the activation of AR-medi-
ated gene transcription [78]. Protein kinase Cβ1 (PKCβ1) 
plays a role in the substrate switching of the KDM1A/
AR complex from H3K4 to H3K9 at target genes by 
phosphorylating H3T6 [80]. AR target genes can also be 
repressed by KDM1A as, unlike ARs, KDM1A resides at 
the promoters of AR target genes, even in the absence of 
androgen treatment, and at that time, these genes are in 
a repressed state [78, 81]. Moreover, a negative feedback 
loop is formed by KDM1A/AR under high androgen lev-
els [82]. In this state, KDM1A is recruited at the enhanc-
ers of target genes by AR and facilitates target gene 
repression by demethylating H3K4 [82].
KDM1A also interacts with estrogen receptor alpha 
(ERα), which is associated with estrogen signaling in 
estrogen-responsive tissues, and any impairment in its 
function can lead to the genesis and progression of vari-
ous types of cancers [83, 84]. KDM1A functions as both 
an activator and repressor of genes in association with 
ERα, similar to the mechanism by which KDM1A associ-
ates with ARs [85].
Because of the interaction of KDM1A with a wide vari-
ety of complexes, it has been suggested that the micro-
environment of KDM1A dictates its substrate specificity 
and leads to the growing functional complexity of this 
FAD-binding demethylase.
Fig. 4 Substrate specificity and regulation of gene expression by KDM1A. The binding of KDM1A to the CoREST and NuRD complex allows the 
demethylation of H3K4me1/2 and leads to the inhibition of target gene expression, but this complex cannot catalyze the demethylation of the 
lysine 9 of histone 3 (H3K9me1/2). The interaction between KDM1A and the androgen and estrogen receptors alters its substrate specificity from 
H3K4me1/2 to H3K9me1/2, allowing for the regulation of target gene expression [18]
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KDM1A–RNA interactions
KDM1A regulates the expression of target genes through 
histone demethylation. In addition to other molecules, 
KDM1A interacts with several RNAs, including microR-
NAs such as miR-137 [25]. miR-137 is expressed in the 
nervous system and is significant for regulation of neural 
stem cell differentiation [58]. It regulates the expression 
of KDM1A by targeting its 3′ untranslated-region (UTR), 
leading to the differentiation of neural embryonic stem 
cells [58]. KDM1A is also involved in the fate determina-
tion of neural stem cells by acting as the TLX corepres-
sor (nuclear receptor subfamily 2 group E member 1) that 
targets miR-137 and inhibits its expression [58]. These 
molecules form a regulatory loop that controls the dif-
ferentiation of neural stem cells. Recently, miR-329 was 
also shown to target the 3′-UTR of KDM1A, suppress-
ing its expression [86]. Notably, in addition to interac-
tions between KDM1A and microRNAs, an association 
between KDM1B and the microRNA miR-215 has also 
been observed [87]. The post-transcriptional induction 
of miR-215 through the HIF-Drosha complex inversely 
correlates with KDM1B expression and plays a role in the 
adaptation of glioma-initiating cells (GICs) to hypoxic 
conditions [87].
In addition to microRNAs, KDM1A interacts with long 
noncoding RNAs (lncRNAs) [88]. lncRNAs have been 
implicated in several types of cancers, and they function 
as regulators of gene transcription by acting as scaffolds 
for chromatin-modifying complexes [89–91]. The over-
expression of the lncRNA HOTAIR has been observed in 
many types of cancer [92]. This noncoding RNA interacts 
with the KDM1A/CoREST complex, mediates its inter-
action with the polycomb repressive complex 2 (PRC2), 
and assists in its recruitment to the HOXD locus [88] to 
downregulate the expression of tumor-suppressor genes 
[93]. Furthermore, the HOTAIR-mediated KDM1A/
PRC2 complex positively regulates the transcription 
factor NFAT5, which is involved in angiogenesis and 
the progression of breast cancer [94]. KDM1A has also 
been found to interact with another breast cancer-asso-
ciated lncRNA, steroid receptor RNA activator (SRA) 
[95]. However, in this case, the interaction is mediated 
by progesterone receptors (PRs) [96]. KDM1A was also 
shown to interact with TERRAs (RNAs encoded by telo-
meric sequences) and plays a role in the DNA damage of 
uncapped telomeres [97].
EMT and the KDM1A microenvironment
EMT is crucial for embryonic development and tumor 
metastasis and is characterized by the alteration/repro-
gramming of epithelial cells [98], which acquire migra-
tory properties and are transformed into mesenchymal 
cells [99]. EMT is a complex process regulated by a num-
ber of factors and signaling pathways and is crucial for 
the development of the neural crest and mesoderm for-
mation [100]; it also plays important roles in carcinogen-
esis and tumor propagation [100]. KDM1A is involved 
in EMT through interactions with the members of the 
SNAI1 family of zinc finger transcription factors, includ-
ing SNAI1 (SNAIL) and SNAI2 (SLUG) [101, 102]. The 
expression of SNAI1 and E-cadherin is a hallmark of 
carcinoma development and metastasis. The downregu-
lation of E-cadherin or both of these proteins occurs fol-
lowing the interaction of SNAI1 with KDM1A. SNAI1 
recruits the KDM1A corepressor complex through its 
SNAG domain, leading to the demethylation of H3K4me2 
in the histone tail of E-cadherin-associated active pro-
moters [101]. The inactivation of E-cadherin promoters 
drives the aberrant development of neural crest cells and 
increases tumor invasion and propagation (Fig.  5). The 
interactions between KDM1A and SNAI1, followed by 
interactions with E-cadherin, enable KDM1A-mediated 
control of carcinogenesis [101].
KDM1A microenvironment in oncogenesis
The complex structure of KDM1A allows it to interact 
with a wide variety of protein complexes, transcription 
factors, hormone receptors, and different types of RNAs. 
Its diverse microenvironment has been implicated in the 
genesis and progression of cancer (Table 1) [20, 103, 104]. 
KDM1A has been studied for its roles in several malig-
nancies, which are described below. While investigations 
into the role of KDM1B in oncogenesis are lacking, the 
enhanced expression of KDM1B has been observed in 
Inacvaon of E-cadherin 
promoters
Aberrant development of neural crest 









Fig. 5 Role of KDM1A in epithelial–mesenchymal transition. 
SNAI1 recruits the KDM1A corepressor complex, leading 
to the demethylation of H3K4me2 in the histone tails of 
E‑cadherin‑associated promoters. This demethylation ultimately 
inactivates these E‑cadherin associated promoters. This 
SNAI1‑mediated interaction of KDM1A with E‑cadherin controls the 
processes of neural development and tumorigenesis
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breast cancer, and its targeted repression is observed in 
glioblastoma [87, 105].
Prostate cancer
Prostate cancer is one of the most common cancers 
in males, and the overexpression of KDM1A plays an 
important role in prostate cancer initiation and progres-
sion [106]. Although there are studies that describe very 
little to no overexpression of KDM1A in prostate can-
cer cell lines [107, 108], the overexpression of KDM1A 
has been found to be associated with prostate cancer 
progression and recurrence [109]. In prostate can-
cer, the substrate specificity of KDM1A changes from 
H3K4me1/2 to H3K9me1/2 through its interactions with 
ARs [110]. The increased expression of KDM1A, accom-
panied by a reduction in E-cadherin expression, can be 
used as a predictive marker for prostate cancer progres-
sion and metastasis [111]. KDM1A regulates the expres-
sion of vascular endothelial growth factor A (VEGF-A), 
which is important in prostate cancer progression [109, 
112]. The enhanced expression of VEGF-A was shown to 
be correlated with KDM1A overexpression [113]. Moreo-
ver, the increase in KDM1A expression is responsible for 
the androgen-independent transition of prostate cancer 
cells (LNCaP) [114], protecting them from apoptosis by 
activating AR signaling and inhibiting p53 signaling [4, 
115]. The inhibition of KDM1A leads to the suppression 
of gene transcription facilitated by ARs and the inhibi-
tion of prostate cancer progression [78].
Neuroblastoma
The most common extracranial solid tumor of childhood 
(neuroblastoma) is associated with aberrant overexpres-
sion of KDM1A [116]. High expression of KDM1A was 
observed in poorly differentiated neuroblastoma cells, 
and downregulation of KDM1A was found in differenti-
ated neuroblastoma cells [117]. However, more detailed 
investigations are required to understand the interaction 
between KDM1A and genes associated with neuroblas-
toma. It has been found that the microRNA miR-137 acts 
to suppress KDM1A expression in neuroblastoma. miR-
137 is expressed at low levels in aggressive neuroblas-
toma tumors but directly targets KDM1A [118]. Thus, 
increasing the expression of miR-137 in neuroblastoma 
cells may serve as an effective therapeutic strategy for the 
treatment of aggressive neuroblastoma [118].
The overexpression of KDM1A has also been observed 
in a tumor closely related to neuroblastoma, i.e., medul-
loblastoma [119]. Medulloblastoma is the leading cause 
of death among childhood malignancies, and currently 
available treatments for this tumor are associated with 
certain neurological disabilities among survivors [119]. 
The targeting of KDM1A in this tumor may lay the foun-
dation for effective medulloblastoma therapy [119].
Glioblastoma
The phosphorylation of KDM1A has been observed dur-
ing the progression of human glioblastoma. Glycogen 
synthase kinase 3β (GSK3β) promotes the de-ubiquitina-
tion of KDM1A by phosphorylation. Ubiquitin-specific 
peptidase 22 (USP22) then recognizes phosphorylated 
KDM1A and stabilizes it by de-ubiquitination [113]. 
An increase in the expression of GSK3β- and USP22-
dependent KDM1A leads to the demethylation of H3K4, 
which further promotes the transcriptional repression of 
bone morphogenetic protein 2 (BMP2), cyclin-depend-
ent kinase inhibitor 1A (CDKN1A), and GATA-binding 
protein 6 (GATA6). KDM1A-mediated transcriptional 
repression of these genes underlies the self-renewal of 
cancer stem cells and glioblastoma progression [113, 
120].
The targeted suppression of KDM1B by miR-215 has 
been observed in glioblastoma initiating cells (GICs) 
that are essential for glioblastoma occurrence and 
Table 1 Roles of KDM1A in oncogenesis
KDM1A interact with different signaling pathways and interacting partners. This interaction enables KDM1A to play role in development of different types of cancers. 
↓ indicates the down regulation while ↑ denotes the upregulated expression of different genes and factors
Type of cancer KDM1A interactions Functional role of KDM1A References
Prostate cancer Androgen receptor ↓E‑cadherin, ↑VEGF‑A [104, 105, 107]
Breast cancer Estrogen receptor (ERα), CAC2, β‑catenin ↓p57Kip2, ↓LEFTY1, ↓BRCA1 [119, 120, 122–124]
Oral cancer E2F1 signaling pathway ↑Cell proliferation [130]
Colorectal cancer Wnt/β‑catenin pathway ↓DKK1, ↑LGR5 [134, 135]
Neuroblastoma miR‑137 ↑Poorly differentiated cells [111, 112]
Glioblastoma GSK3β ↓BMP2, ↓CDKN1A, ↓GATA6 [107, 114]
Acute myeloid leukemia MLL‑AF9 ↑Activation of oncogenes [145]
T‑cell acute lymphoid leukemia Notch signaling pathway, TAL1/SCL ↑Activation and ↓repression of 
Notch target genes
[61, 62, 150]
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re-occurrence [87]. miR-215 is post-transcriptionally 
induced by hypoxia-inducible factor (HIF) via interac-
tions with the HIF-Drosha complex [87]. The enhanced 
expression of miR-215 is negatively correlated with 
KDM1B expression and positively correlated with HIF1α 
expression in glioblastoma progression [87].
Breast cancer
Breast cancer is among the most common malignancies 
associated with an increased mortality rate in women 
[121, 122]. The formation and progression of breast 
cancer is influenced by different genetic and epigenetic 
abnormalities [123]. The overexpression of KDM1A 
can be considered an early event in breast cancer tumo-
rigenesis [124]. H3K4 demethylation by KDM1A affects 
the expression of the p57Kip2 gene, which encodes a 
cyclin-dependent kinase inhibitor that is essential for 
breast tumor development [125]. KDM1A expression is 
also required for the proper functioning of ERα, which is 
highly expressed in the majority of breast tumors [126]. 
The recruitment of estrogen-bound ERα to estrogen-
responsive gene promoters is attenuated by the inhibi-
tion of KDM1A, and this exerts anti-proliferative effects 
in breast cancer [127]. Moreover, CDK2-associated cullin 
(CAC2) interacts with KDM1A and decreases the func-
tion of ERα co-activator [128]. Additionally, KDM1A 
interacts with β-catenin and regulates the expression of 
the tumor-suppressor gene LEFTY1 [129]. The mRNA 
levels of KDM1A and β-catenin are inversely correlated 
with the expression of LEFTY1.
KDM1A overexpression has been observed in  ER− 
breast cancers as well and was shown to correlate with 
a reduction in BRCA1 (a familial susceptibility gene 
for breast cancer) expression [130]. The dysregulation 
of BRCA1 expression induces a basal-like phenotype 
in breast cancer cells. Ubiquitin-specific peptidase 28 
(USP28) plays a role in the stabilization of KDM1A in 
multiple cancers, including breast cancer, through its de-
ubiquitination [131]. The phosphorylation of KDM1A 
at Ser112 is required for breast cancer metastasis, as 
the phosphorylated protein inhibits E-cadherin expres-
sion [132]. The increased expression of histone-modi-
fying enzymes, such as KDM1A, histone deacetylase 2 
(HDAC2), and NAD-dependent deacetylase sirtuin-1 
(SIRT1), was observed in breast cancer samples, and 
their overexpression was shown to be associated with 
reduced survival and a shorter period of tumor relapse 
[133]. Furthermore, the expression levels of KDM1A 
and HDAC isozymes are correlated, i.e., KDM1A knock-
down induces a decrease in the expression of HDAC5 in 
triple-negative breast cancer [134], while the depletion 
of HDAC5 leads to the accumulation of H3K4me2 [134]. 
This suggests that KDM1A and HDAC may represent 
potential prognostic factors for breast carcinogenesis.
In addition to KDM1A, its homolog KDM1B is highly 
expressed in breast cancer, particularly in invasive tumors 
[105]. The enhanced expression of KDM1B in MDA-
MB-231 cells has been shown to alter the expression of 
key epigenetic regulators, i.e., KDM1A, HDAC1/2, and 
DNMT3B; stimulate cellular proliferation; and enhance 
colony formation in soft agar while decreasing motility 
and invasion [135]. Additionally, KDM1B overexpression 
in MDA-MB-231 cells led to increased tumor growth, 
facilitated mammosphere formation, and resulted in 
the induction of pluripotent stem cell markers, i.e., 
NANOG and SOX2. Thus, KDM1B also plays significant 
and multifaceted roles in breast cancer progression and 
the enrichment of cancer stem cells [135]. Knockout of 
KDM1B increases the expression of many key silenced 
genes that are significant in breast cancer development 
[105]. However, a detailed investigation of the underly-
ing mechanism of KDM1B in breast cancer metastasis is 
needed.
Oral cancer
Oral cancer is the most common cancer among devel-
oping countries, and KDM1A expression is upregulated 
in oral tumors compared to levels in normal oral tissues 
[136]. KDM1A regulates the E2F1 signaling pathway in 
oral cancer and increases cell proliferation [137]. More-
over, the inhibition of KDM1A alleviates E2F1 signaling 
activities, and its overexpression leads to poor clinical 
outcomes [137]. KDM1A serves as a novel biomarker and 
early prognostic factor for oral and tongue cancer [138].
Colorectal cancer
The enhanced expression of KDM1A is also observed in 
colon and colorectal tumors [139, 140]. KDM1A plays a 
role in activating the Wnt/β-catenin signaling pathway, 
but, at the same time, downregulates the signaling path-
way antagonistic to the colorectal cancer-related gene 
dickkopf-1 (DKK1) [141]. Moreover, increased expres-
sion of KDM1A is also associated with the expression of 
leucine-rich repeat-containing G-protein-coupled recep-
tor 5 (LGR5), a well-known colorectal cancer stem cell 
marker [142]. The inhibition of KDM1A attenuates Wnt/
β-catenin signaling and diminishes colorectal cancer 
progression by downregulating the expression of LGR5 
[142].
The expression of KDM1A is also associated with 
reduced expression of CDH1, which results in colon can-
cer metastasis [139]. Moreover, the upregulated expres-
sion of KDM1A significantly reduced the expression of 
E-cadherin in samples of advanced colon cancer and dis-
tant metastases [139].
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KDM1A in other malignancies and sarcomas
The enhanced expression of KDM1A has also been 
observed in pancreatic cancer [117], non-small-cell 
lung carcinoma [143, 144], and human epithelial ovar-
ian cancer [145]. Furthermore, KDM1A was shown to 
be involved in bladder cancer [146], while the immu-
noreactivity of KDM1A was shown to be elevated in 
hepatocellular carcinoma [147]. The upregulation of 
KDM1A is also observed in chondrosarcoma, Ewing’s 
sarcoma, and osteosarcoma [148]. Moreover, a US Food 
and Drug Administration-approved drug that inhibits 
KDM1A was also found to inhibit chondrosarcoma, 
Ewing’s sarcoma, osteosarcoma, and rhabdomyosar-
coma cell growth in  vitro [148]. These results demon-
strate that KDM1A represents an important epigenetic 
regulator that is essential for cell growth and differenti-
ation due to its interactions with various factors. These 
KDM1A-induced alterations in gene expression levels 
are associated with cellular oncogenic potential.
KDM1A in acute myeloid leukemia (AML)
Hematopoiesis is a complex process regulated by vari-
ous epigenetic modifiers [149]. During physiological 
hematopoiesis, alterations in gene expression in stem 
cells are responsible for the differentiation of mature 
blood cell lineages and removal of the stem cell iden-
tity [66]. In AML, hematopoietic stem cell control is 
disturbed, and these stem cells develop in an unlim-
ited manner, exhibiting self-renewal, increased prolif-
eration, and poor differentiation [150]. KDM1A and the 
mixed-lineage leukemia gene (MLL) play a role in cell 
differentiation during hematopoiesis [151].
Experimental mouse and human studies of MLL-AF9 
leukemia have demonstrated that KDM1A-knockout 
cells differentiate efficiently and do not form colonies 
[152]. The accumulation of H3K4me2 at the promoter 
region of MLL-AF9 was observed in the absence of 
KDM1A [153]. The expression of KDM1A was shown to 
be associated with the activation of oncogenes specific 
for leukemia stem cells [151, 154]. Moreover, KDM1A 
is an effective drug target for AML therapy [153]. A 
number of KDM1A inhibitors have been investigated 
for their potential to inhibit growth in AML by induc-
ing KDM1A inhibition [155]. However, single-agent 
therapy is not suitable for AML because it is associated 
with an increased risk of remission [156, 157]. Hence, 
combinatorial approaches including HDAC inhibitors 
are under investigation for curative treatment of AML 
[158]. In addition, the activation of oncogenic target 
gene programs and the recruitment of various protein 
complexes by KDM1A should be further studied.
KDM1A in T cell acute lymphoid leukemia (T‑ALL)
KDM1A overexpression has been observed in T-ALL, 
in which it was shown to be characterized by aber-
rant Notch signaling and T-cell progenitor malignancy 
[66], originating from mutations in the NOTCH1 gene. 
KDM1A is a part of the multifunctional Notch com-
plex, acting as a NOTCH1 target gene modifier [159]. 
KDM1A-mediated gene activation and repression 
has been observed in T-ALL [160]. The activation of 
NOTCH1 target genes by DNA-binding complex CSL 
occurs in the presence of NOTCH1, whereby KDM1A 
preferentially targets H3K9me2, while in the absence of 
NOTCH1, KDM1A demethylates H3K4me2 residues, 
leading to the suppression of NOTCH1 target gene 
expression [161]. Therefore, KDM1A acts as a mechanis-
tic switch for the activation and repression of NOTCH1 
target genes. The inhibition of KDM1A is associated with 
growth arrest and alterations in T-ALL, similar to the 
effects of NOTCH1 silencing [160].
The association of KDM1A with the hematopoietic 
stem cell transcription factor TAL1/SCL was shown to 
be important in the differentiation of stem cells, while 
its deregulation was associated with T-ALL development 
[65]. The phosphorylation of TAL1 at Ser172 by protein 
kinase A (PKA) induces the dissociation of KDM1A/
TAL1, consequently activating target genes by inducing 
the expression of H3K4me2 in promoter regions [66].
KDM1A as a therapeutic target and associated challenges
The identification of functional significance of KDM1A 
in various malignancies and developmental disorders 
shows that this demethylase may represent a potent ther-
apeutic target. The development of an efficient KDM1A 
inhibitor is in progress [162]. The structural similar-
ity between monoamine oxidases (MAOs) and KDM1A 
has led to the investigation of anti-MAO compounds as 
inhibitors of KDM1A. Tranylcypromine, an MAO inhibi-
tor, can inhibit KDM1A activity, although its inhibitory 
potential is low. However, it represents a lead compound 
in many studies, leading to the development of a number 
of KDM1A-targeting derivatives [163]. These compounds 
inhibit the activity of KDM1A through the covalent mod-
ification of its cofactor, FAD. The addition of side groups 
to the phenyl ring or the N-alkylation of tranylcypromine 
derivatives has been shown to increase the efficacy of 
KDM1A inhibitors [164]. In addition to tranylcypromine, 
other compounds that may inhibit KDM1A include other 
MAO inhibitors such as pargyline, peptide- and poly-
amine-based inhibitors, non-peptidic propargylamines, 
non-peptidic compounds mimicking histone tails, benzo-
hydrazides, phenyloxazole derivatives, amino thiazoles, 
thiazole sulfonamides, triazole dithiocarbamate hybrids, 
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pyrimidine thiourea hybrids, namoline, and geranyl 
geranoic acid [164]. Propargylamines, which are pep-
tide- and polyamine-based inhibitors, inhibit KDM1A 
as suicide inhibitory compounds through the covalent 
modification of FAD. Derivatives of hydrazines, such as 
benzohydrazides, have been found to be the most effec-
tive inhibitors of KDM1A [165]. These hybrids represent 
a novel class of inhibitors with anticancer properties, 
exhibiting considerable demethylase inhibition potential 
[114].
In addition to the above-mentioned KDM1A inhibitors, 
many potent KDM1A inhibitors with  IC50 values in the 
nanomolar range (9.8–77 nM) have been found with the 
ability to inhibit the proliferation of MLL-rearranged leu-
kemia cells [155]. These inhibitors exhibit  EC50 values in 
the range of 10–350 nM but are non-toxic to many other 
tumor cells [155]. These inhibitory compounds belong 
to the cyclopropylamine series, and they are extremely 
selective for MLL-rearranged leukemia cells. Further-
more, these cyclopropylamine-based compounds do not 
exert toxicity, in contrast to many other KDM1A inhibi-
tors, and hence, they may serve as useful therapeutics for 
MLL-rearranged leukemia cells [155]. Although KDM1A 
is a candidate target for treating MLL involving KDM1A, 
however treatment with KDM1A inhibitor alone is asso-
ciated with risk of toxicity and many other side effects 
[157]. Recent studies have suggested combinatorial thera-
pies, i.e., approaches involving the inhibition of DOT1L 
(an H3K79 methyltransferase) and the bromo-domain 
protein BRD4, together with the inhibition of KDM1A, to 
treat MLL-rearranged leukemia [166].
Moreover, as with MLL, KDM1A is a potential drug tar-
get in other subtypes of AML [167]. In the case of acute 
promyelocytic leukemia (APML), the use of all-trans reti-
noic acid (ATRA) to induce the differentiation of leuke-
mic blasts is a standard therapy, but it is associated with 
remission risk [157]. ATRA alone is insufficient as a cure, 
and synergistic therapy with anthracycline or arsenic tri-
oxide is required [157]. In the case of AML, single-agent 
treatment is rarely curative. Hence, treatment requires 
other options, such as the inhibition of KDM1A together 
with chemotherapies historically effective for APML 
therapy. Concomitant drug treatment (a KDM1A inhibi-
tor together with an HDAC inhibitor) is another alterna-
tive option, as the inhibition of KDM1A aggravates the 
cell cycle arrest and apoptosis of breast cancer and glio-
blastoma cells induced by HDAC inhibitors [153, 167, 
168]. The side effects of anemia and thrombocytopenia 
in response to this concomitant therapy can be treated 
by transfusions. SP2509 is a novel KDM1A antagonist, 
and its treatment attenuates the association of KDM1A 
with CoREST, along with enhancing H3K4Me3 in gene 
promoters and increasing p21, p27, and C/EBPα levels in 
cultured AML cells [158]. Moreover, treatment with this 
novel KDM1A antagonist inhibited the growth of AML 
colony cells and induced differentiation in cultured, as 
well as primary, AML blasts [169]. However, in contrast 
to MLL fusion protein treatment, SP2509 treatment trig-
gered apoptosis in AML cells expressing mutant NPM1 
[170]. Although SP2509 is an effective agent for treating 
AML, concomitant treatment with the pan-HDAC inhib-
itor panobinostat (PS) enhanced the efficiency of each 
agent as compared to that of each agent alone [171, 172]. 
Co-treatment of PS and SP2509 effectively improved the 
survival of mice engrafted with human AML cells with-
out exerting any toxicity [158]. Thus, concomitant inhibi-
tor treatment may serve as an effective and promising 
therapy against AML, although further investigation and 
preclinical trials are warranted with the aim of identify-
ing an effective KDM1A inhibitor with improved potency 
and reduced side effects.
In the case of small-cell lung cancer (SCLC), a cyclo-
propylamine-based KDM1A inhibitor, GSK2879552, was 
recently discovered to serve as a mechanism-based irre-
versible inactivator of KDM1A [144]. The DNA hypo-
methylation of a signature set of probes was observed 
in SCLC cell lines that exhibited growth inhibition in 
response to GSK2879552 treatment [144]. Hence, the dis-
covery of this small potent inhibitor of KDM1A suggests 
that it may serve as a predictive biomarker. Although 
GSK2879552 is currently under clinical development to 
investigate the anti-tumor potential of KDM1A inhibi-
tion in SCLC, this targeted mechanistic approach in com-
bination with its role as a predictive biomarker makes the 
inhibition of KDM1A an exciting therapeutic drug tar-
get for SCLC treatment [144]. To date, three inhibitors 
of KDM1A are undergoing phase I clinical trials for the 
treatment of AML and SCLC [165].
In addition to the outlined issues, one further challenge 
is the targeting of the CoREST/KDM1A complex, which 
is involved in several functions and interacts with sev-
eral protein complexes [173]. The identification of novel 
inhibitors with mechanisms of action other than the for-
mation of covalent/non-covalent interactions may aid in 
the development of KDM1A-targeting drugs.
Conclusions
KDM1A is a unique epigenetic modifier with the abil-
ity to maintain interactions with a variety of differ-
ent protein complexes, noncoding RNAs, microRNAs, 
and transcription factors. The functional significance 
of KDM1A is maintained by its interactions at multiple 
sites in the genome, particularly its binding to promot-
ers and enhancers. The complex and unique structure 
of KDM1A enables its binding to various other pro-
tein complexes and the inhibition or activation of gene 
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expression. The interaction of KDM1A with different 
promoters, transcription factors, and protein complexes 
allows this protein to control the cellular oncogenic pro-
gram as an important epigenetic modifier. Moreover, the 
involvement of KDM1A in oncogenesis and development 
make it an attractive therapeutic target. Detailed inves-
tigation of KDM1A as an epigenetic modifier and the 
mechanisms underlying its activity represents a major 
research challenge. In summary, the analysis of KDM1A-
containing repressive and stimulatory complexes and the 
identification of molecular signals that affect the func-
tion of KDM1A-containing complexes are necessary for 
a complete understanding of epigenetic modifications 
and their roles in stem cell differentiation and oncogenic 
progression.
Abbreviations
FAD: flavin adenine dinucleotide; KDM1A: lysine‑specific histone demethylase 
1A; AOL: amine oxidase‑like domain; SWIRM: Swi3p/Rsc8p/Moira domain/
small alpha helical domain; DNMT1: DNA methyltransferase 1; CoREST: 
RE1‑silencing transcription factor (REST) corepressor; NuRd: Mi‑/nucleosome 
remodeling and deacetylase; AR & ER: androgen & estrogen receptors; HDAC1: 
histone deacetylase 1; TAL1: T cell acute lymphocytic leukemia protein‑1; EMT: 
epithelial–mesenchymal transition; UTR : untranslated region; TERRAs: RNAs 
encoded by telomeric sequences; VEGF‑A: vascular endothelial growth factor 
A; LNCaP: lymph node carcinoma of prostate; DKK1: Dickkopf‑1; LGR5: leucine‑
rich repeat‑containing G‑protein‑coupled receptor 5; GSK3β: glycogen 
synthase kinase 3β; USP22 & 28: ubiquitin‑specific peptidase 22 & 28; BMP2: 
bone morphogenetic protein 2; CDKN1A: cyclin‑dependent kinase inhibitor 
1A; GATA6: GATA binding protein 6; SIRT1: NAD‑dependent deacetylase 
sirtuin‑1; AML: acute myeloid leukemia; MLL: mixed‑lineage leukemia; T‑ALL: 
T cell acute lymphoid leukemia; PKA: protein kinase A; MAO: monoamine 
oxidase; SCLC: small‑cell lung cancer.
Authors’ contributions
TI, H‑KL, CK, and H‑SL wrote the manuscript and prepared figures. TK, T‑JP, 
and H‑SL developed the central idea for the paper, critically analyzed it, and 





The authors declare that they have no competing interests.




Ethics approval and consent to participate
Not applicable.
Funding
This study was funded by the National Research Foundation of Korea (NRF) 
(Grant No. NRF‑2015R1A2A1A10053265) and the Ministry of Science, ICT, and 
Future Planning (MSIP) (Grant No. 2015R1A4A1042271), the Republic of Korea.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 31 January 2018   Accepted: 12 June 2018
References
 1. Xie P, Zang LQ, Li XK, Shu Q. An epigenetic view of developmental 
diseases: new targets, new therapies. World J Pediatr. 2016;12:291–7.
 2. Perri F, Longo F, Giuliano M, Sabbatino F, Favia G, Ionna F, Addeo R, Della 
Vittoria Scarpati G, Di Lorenzo G, Pisconti S. Epigenetic control of gene 
expression: potential implications for cancer treatment. Crit Rev Oncol 
Hematol. 2017;111:166–72.
 3. Mohammed SI, Springfield S, Das R. Role of epigenetics in cancer health 
disparities. Methods Mol Biol. 2012;863:395–410.
 4. Cai C, Yuan X, Balk SP. Androgen receptor epigenetics. Transl Androl 
Urol. 2013;2:148–57.
 5. Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation 
dynamics: establishment, regulation, and biological impact. Mol Cell. 
2012;48:491–507.
 6. Cohen I, Poreba E, Kamieniarz K, Schneider R. Histone modifiers in 
cancer: friends or foes? Genes Cancer. 2011;2:631–47.
 7. Khan SA, Reddy D, Gupta S. Global histone post‑translational modifica‑
tions and cancer: biomarkers for diagnosis, prognosis and treatment? 
World J Biol Chem. 2015;6:333–45.
 8. Kouzarides T. Chromatin modifications and their function. Cell. 
2007;128:693–705.
 9. Meier K, Brehm A. Chromatin regulation: how complex does it get? 
Epigenetics. 2014;9:1485–95.
 10. Upadhyay AK, Cheng X. Dynamics of histone lysine methylation: struc‑
tures of methyl writers and erasers. Prog Drug Res. 2011;67:107–24.
 11. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, 
Shi Y. Histone demethylation mediated by the nuclear amine oxidase 
homolog LSD1. Cell. 2004;119:941–53.
 12. Agger K, Christensen J, Cloos PA, Helin K. The emerging functions of 
histone demethylases. Curr Opin Genet Dev. 2008;18:159–68.
 13. Hou H, Yu H. Structural insights into histone lysine demethylation. Curr 
Opin Struct Biol. 2010;20:739–48.
 14. Maiques‑Diaz A, Somervaille TC. LSD1: biologic roles and therapeutic 
targeting. Epigenomics. 2016;8:1103–16.
 15. Kooistra SM, Helin K. Molecular mechanisms and potential functions of 
histone demethylases. Nat Rev Mol Cell Biol. 2012;13:297–311.
 16. Adamo A, Barrero MJ, Izpisua Belmonte JC. LSD1 and pluripotency: a 
new player in the network. Cell Cycle. 2011;10:3215–6.
 17. Foster CT, Dovey OM, Lezina L, Luo JL, Gant TW, Barlev N, Bradley A, 
Cowley SM. Lysine‑specific demethylase 1 regulates the embryonic 
transcriptome and CoREST stability. Mol Cell Biol. 2010;30:4851–63.
 18. Amente S, Lania L, Majello B. The histone LSD1 demethylase in 
stemness and cancer transcription programs. Biochim Biophys Acta. 
2013;1829:981–6.
 19. Burg JM, Link JE, Morgan BS, Heller FJ, Hargrove AE, McCafferty DG. 
KDM1 class flavin‑dependent protein lysine demethylases. Biopolymers. 
2015;104:213–46.
 20. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, 
Neal DE, Yamaue H, Ponder BA, et al. Overexpression of LSD1 contrib‑
utes to human carcinogenesis through chromatin regulation in various 
cancers. Int J Cancer. 2011;128:574–86.
 21. Karytinos A, Forneris F, Profumo A, Ciossani G, Battaglioli E, Binda C, 
Mattevi A. A novel mammalian flavin‑dependent histone demethylase. 
J Biol Chem. 2009;284:17775–82.
 22. Laurent B, Shi Y. Expression, purification, and biochemical analy‑
sis of the LSD1/KDM1A histone demethylase. Methods Enzymol. 
2016;573:241–59.
 23. Culhane JC, Cole PA. LSD1 and the chemistry of histone demethylation. 
Curr Opin Chem Biol. 2007;11:561–8.
 24. Aravind L, Iyer LM. The SWIRM domain: a conserved module found in 
chromosomal proteins points to novel chromatin‑modifying activities. 
Genome Biol. 2002;3:research0039.1–research0039.7.
 25. Marabelli C, Marrocco B, Mattevi A. The growing structural and func‑
tional complexity of the LSD1/KDM1A histone demethylase. Curr Opin 
Struct Biol. 2016;41:135–44.
Page 12 of 15Ismail et al. Epigenetics & Chromatin  (2018) 11:33 
 26. Fang R, Barbera AJ, Xu Y, Rutenberg M, Leonor T, Bi Q, Lan F, Mei P, 
Yuan GC, Lian C, et al. Human LSD2/KDM1b/AOF1 regulates gene 
transcription by modulating intragenic H3K4me2 methylation. Mol Cell. 
2010;39:222–33.
 27. Chen Y, Yang Y, Wang F, Wan K, Yamane K, Zhang Y, Lei M. Crystal struc‑
ture of human histone lysine‑specific demethylase 1 (LSD1). Proc Natl 
Acad Sci U S A. 2006;103:13956–61.
 28. Stavropoulos P, Blobel G, Hoelz A. Crystal structure and mecha‑
nism of human lysine‑specific demethylase‑1. Nat Struct Mol Biol. 
2006;13:626–32.
 29. Yang M, Gocke CB, Luo X, Borek D, Tomchick DR, Machius M, Otwin‑
owski Z, Yu H. Structural basis for CoREST‑dependent demethylation 
of nucleosomes by the human LSD1 histone demethylase. Mol Cell. 
2006;23:377–87.
 30. Zhang X, Wen H, Shi X. Lysine methylation: beyond histones. Acta 
Biochim Biophys Sin (Shanghai). 2012;44:14–27.
 31. You A, Tong JK, Grozinger CM, Schreiber SL. CoREST is an integral com‑
ponent of the CoREST‑human histone deacetylase complex. Proc Natl 
Acad Sci U S A. 2001;98:1454–8.
 32. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil 
S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL. p53 is regulated by 
the lysine demethylase LSD1. Nature. 2007;449:105–8.
 33. Burg JM, Gonzalez JJ, Maksimchuk KR, McCafferty DG. Lysine‑specific 
demethylase 1A (KDM1A/LSD1): product recognition and kinetic analy‑
sis of full‑length histones. Biochemistry. 2016;55:1652–62.
 34. Chen Y, Damayanti NP, Irudayaraj J, Dunn K, Zhou FC. Diversity of two 
forms of DNA methylation in the brain. Front Genet. 2014;5:46.
 35. Hwang S, Schmitt AA, Luteran AE, Toone EJ, McCafferty DG. Thermody‑
namic characterization of the binding interaction between the histone 
demethylase LSD1/KDM1 and CoREST. Biochemistry. 2011;50:546–57.
 36. Lohse B, Helgstrand C, Kristensen JB, Leurs U, Cloos PA, Kristensen JL, 
Clausen RP. Posttranslational modifications of the histone 3 tail and 
their impact on the activity of histone lysine demethylases in vitro. PLoS 
ONE. 2013;8:e67653.
 37. Pilotto S, Speranzini V, Tortorici M, Durand D, Fish A, Valente S, Forneris 
F, Mai A, Sixma TK, Vachette P, Mattevi A. Interplay among nucleosomal 
DNA, histone tails, and corepressor CoREST underlies LSD1‑mediated 
H3 demethylation. Proc Natl Acad Sci U S A. 2015;112:2752–7.
 38. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone 
demethylase activity by its associated factors. Mol Cell. 2005;19:857–64.
 39. Kontaki H, Talianidis I. Lysine methylation regulates E2F1‑induced cell 
death. Mol Cell. 2010;39:152–60.
 40. Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, Su H, Sun W, Chang H, Xu 
G, et al. The lysine demethylase LSD1 (KDM1) is required for mainte‑
nance of global DNA methylation. Nat Genet. 2009;41:125–9.
 41. Luka Z, Pakhomova S, Loukachevitch LV, Calcutt MW, Newcomer ME, 
Wagner C. Crystal structure of the histone lysine specific demethylase 
LSD1 complexed with tetrahydrofolate. Protein Sci. 2014;23:993–8.
 42. Fang R, Chen F, Dong Z, Hu D, Barbera AJ, Clark EA, Fang J, Yang Y, Mei P, 
Rutenberg M, et al. LSD2/KDM1B and its cofactor NPAC/GLYR1 endow a 
structural and molecular model for regulation of H3K4 demethylation. 
Mol Cell. 2013;49:558–70.
 43. Zhang Q, Qi S, Xu M, Yu L, Tao Y, Deng Z, Wu W, Li J, Chen Z, Wong J. 
Structure‑function analysis reveals a novel mechanism for regulation of 
histone demethylase LSD2/AOF1/KDM1b. Cell Res. 2013;23:225–41.
 44. Yang Z, Jiang J, Stewart MD, Qi S, Yamane K, Li J, Zhang Y, Wong J. AOF1 
is a histone H3K4 demethylase possessing demethylase activity‑inde‑
pendent repression function. Cell Res. 2010;20:276–87.
 45. He F, Umehara T, Saito K, Harada T, Watanabe S, Yabuki T, Kigawa 
T, Takahashi M, Kuwasako K, Tsuda K, et al. Structural insight into 
the zinc finger CW domain as a histone modification reader. 
Structure. 2010;18:1127–39.
 46. Hoppmann V, Thorstensen T, Kristiansen PE, Veiseth SV, Rahman MA, 
Finne K, Aalen RB, Aasland R. The CW domain, a new histone recogni‑
tion module in chromatin proteins. EMBO J. 2011;30:1939–52.
 47. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL. Chromatin 
deacetylation by an ATP‑dependent nucleosome remodelling complex. 
Nature. 1998;395:917–21.
 48. Hakimi MA, Bochar DA, Chenoweth J, Lane WS, Mandel G, Shiekhattar 
R. A core‑BRAF35 complex containing histone deacetylase mediates 
repression of neuronal‑specific genes. Proc Natl Acad Sci U S A. 
2002;99:7420–5.
 49. Hakimi MA, Dong Y, Lane WS, Speicher DW, Shiekhattar R. A can‑
didate X‑linked mental retardation gene is a component of a new 
family of histone deacetylase‑containing complexes. J Biol Chem. 
2003;278:7234–9.
 50. Shi Y, Sawada J, Sui G, el Affar B, Whetstine JR, Lan F, Ogawa H, Luke 
MP, Nakatani Y. Coordinated histone modifications mediated by a 
CtBP co‑repressor complex. Nature. 2003;422:735–8.
 51. Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for 
CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature. 
2005;437:432–5.
 52. Barrios AP, Gomez AV, Saez JE, Ciossani G, Toffolo E, Battaglioli E, Mat‑
tevi A, Andres ME. Differential properties of transcriptional complexes 
formed by the CoREST family. Mol Cell Biol. 2014;34:2760–70.
 53. Upadhyay G, Chowdhury AH, Vaidyanathan B, Kim D, Saleque S. 
Antagonistic actions of Rcor proteins regulate LSD1 activity and cel‑
lular differentiation. Proc Natl Acad Sci U S A. 2014;111:8071–6.
 54. Humphrey GW, Wang Y, Russanova VR, Hirai T, Qin J, Nakatani Y, 
Howard BH. Stable histone deacetylase complexes distinguished by 
the presence of SANT domain proteins CoREST/kiaa0071 and Mta‑L1. 
J Biol Chem. 2001;276:6817–24.
 55. Islam MM, Zhang CL. TLX: a master regulator for neural stem 
cell maintenance and neurogenesis. Biochim Biophys Acta. 
2015;1849:210–6.
 56. Yokoyama A, Takezawa S, Schule R, Kitagawa H, Kato S. Transrepres‑
sive function of TLX requires the histone demethylase LSD1. Mol Cell 
Biol. 2008;28:3995–4003.
 57. Sun G, Alzayady K, Stewart R, Ye P, Yang S, Li W, Shi Y. Histone dem‑
ethylase LSD1 regulates neural stem cell proliferation. Mol Cell Biol. 
2010;30:1997–2005.
 58. Sun G, Ye P, Murai K, Lang MF, Li S, Zhang H, Li W, Fu C, Yin J, Wang A, 
et al. miR‑137 forms a regulatory loop with nuclear receptor TLX and 
LSD1 in neural stem cells. Nat Commun. 2011;2:529.
 59. Hu X, Ybarra R, Qiu Y, Bungert J, Huang S. Transcriptional regulation 
by TAL1: a link between epigenetic modifications and erythropoiesis. 
Epigenetics. 2009;4:357–61.
 60. Huang S, Qiu Y, Shi Y, Xu Z, Brandt SJ. P/CAF‑mediated acetylation 
regulates the function of the basic helix‑loop‑helix transcription fac‑
tor TAL1/SCL. EMBO J. 2000;19:6792–803.
 61. Huang S, Qiu Y, Stein RW, Brandt SJ. p300 functions as a tran‑
scriptional coactivator for the TAL1/SCL oncoprotein. Oncogene. 
1999;18:4958–67.
 62. Huang S, Brandt SJ. mSin3A regulates murine erythroleukemia cell 
differentiation through association with the TAL1 (or SCL) transcription 
factor. Mol Cell Biol. 2000;20:2248–59.
 63. O’Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leuke‑
mia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell. 
2004;5:587–96.
 64. Cai Y, Xu Z, Xie J, Ham AJ, Koury MJ, Hiebert SW, Brandt SJ. Eto2/MTG16 
and MTGR1 are heteromeric corepressors of the TAL1/SCL transcription 
factor in murine erythroid progenitors. Biochem Biophys Res Commun. 
2009;390:295–301.
 65. Hu X, Li X, Valverde K, Fu X, Noguchi C, Qiu Y, Huang S. LSD1‑mediated 
epigenetic modification is required for TAL1 function and hematopoie‑
sis. Proc Natl Acad Sci U S A. 2009;106:10141–6.
 66. Li Y, Deng C, Hu X, Patel B, Fu X, Qiu Y, Brand M, Zhao K, Huang S. 
Dynamic interaction between TAL1 oncoprotein and LSD1 regulates 
TAL1 function in hematopoiesis and leukemogenesis. Oncogene. 
2012;31:5007–18.
 67. Chinnadurai G. Transcriptional regulation by C‑terminal binding pro‑
teins. Int J Biochem Cell Biol. 2007;39:1593–607.
 68. Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG, Krones A, Ohgi 
KA, Zhu P, Garcia‑Bassets I, et al. Opposing LSD1 complexes function in 
developmental gene activation and repression programmes. Nature. 
2007;446:882–7.
 69. Banck MS, Li S, Nishio H, Wang C, Beutler AS, Walsh MJ. The ZNF217 
oncogene is a candidate organizer of repressive histone modifiers. 
Epigenetics. 2009;4:100–6.
 70. Chinnadurai G. The transcriptional corepressor CtBP: a foe of multiple 
tumor suppressors. Cancer Res. 2009;69:731–4.
Page 13 of 15Ismail et al. Epigenetics & Chromatin  (2018) 11:33 
 71. Ray SK, Li HJ, Metzger E, Schule R, Leiter AB. CtBP and associated LSD1 
are required for transcriptional activation by NeuroD1 in gastrointesti‑
nal endocrine cells. Mol Cell Biol. 2014;34:2308–17.
 72. Cowger JJ, Zhao Q, Isovic M, Torchia J. Biochemical characterization 
of the zinc‑finger protein 217 transcriptional repressor complex: 
identification of a ZNF217 consensus recognition sequence. Oncogene. 
2007;26:3378–86.
 73. Gocke CB, Yu H. ZNF198 stabilizes the LSD1‑CoREST‑HDAC1 com‑
plex on chromatin through its MYM‑type zinc fingers. PLoS ONE. 
2008;3:e3255.
 74. Basta J, Rauchman M. The nucleosome remodeling and deacetylase 
complex in development and disease. Transl Res. 2015;165:36–47.
 75. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, Liang J, Sun L, Yang X, Shi 
L, et al. LSD1 is a subunit of the NuRD complex and targets the metas‑
tasis programs in breast cancer. Cell. 2009;138:660–72.
 76. Allen HF, Wade PA, Kutateladze TG. The NuRD architecture. Cell Mol Life 
Sci. 2013;70:3513–24.
 77. Li Q, Shi L, Gui B, Yu W, Wang J, Zhang D, Han X, Yao Z, Shang Y. Binding 
of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angio‑
genesis and metastasis in breast cancer cells by repressing chemokine 
CCL14. Cancer Res. 2011;71:6899–908.
 78. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, 
Gunther T, Buettner R, Schule R. LSD1 demethylates repressive histone 
marks to promote androgen‑receptor‑dependent transcription. Nature. 
2005;437:436–9.
 79. Zhou Y, Bolton EC, Jones JO. Androgens and androgen receptor signal‑
ing in prostate tumorigenesis. J Mol Endocrinol. 2015;54:R15–29.
 80. Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, Muller 
JM, Greschik H, Kirfel J, Ji S, et al. Phosphorylation of histone H3T6 
by PKCbeta(I) controls demethylation at histone H3K4. Nature. 
2010;464:792–6.
 81. Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, Jenuwein T, Vogler 
C, Schneider R, Gunther T, Buettner R, et al. Cooperative demethylation 
by JMJD2C and LSD1 promotes androgen receptor‑dependent gene 
expression. Nat Cell Biol. 2007;9:347–53.
 82. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Nelson PS, Liu XS, 
Brown M, Balk SP. Androgen receptor gene expression in prostate 
cancer is directly suppressed by the androgen receptor through recruit‑
ment of lysine‑specific demethylase 1. Cancer Cell. 2011;20:457–71.
 83. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer 
biology and therapy. Nat Rev Cancer. 2011;11:597–608.
 84. Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, Chiariotti 
L, Malorni A, Abbondanza C, Avvedimento EV. DNA oxidation as 
triggered by H3K9me2 demethylation drives estrogen‑induced gene 
expression. Science. 2008;319:202–6.
 85. Garcia‑Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, Cheng CS, 
Ju BG, Ohgi KA, Wang J, Escoubet‑Lozach L, et al. Histone methylation‑
dependent mechanisms impose ligand dependency for gene activa‑
tion by nuclear receptors. Cell. 2007;128:505–18.
 86. Yang H, Li Q, Zhao W, Yuan D, Zhao H, Zhou Y. miR‑329 suppresses the 
growth and motility of neuroblastoma by targeting KDM1A. FEBS Lett. 
2014;588:192–7.
 87. Hu J, Sun T, Wang H, Chen Z, Wang S, Yuan L, Liu T, Li HR, Wang P, Feng Y, 
et al. MiR‑215 Is induced post‑transcriptionally via HIF‑Drosha complex 
and mediates glioma‑initiating cell adaptation to hypoxia by targeting 
KDM1B. Cancer Cell. 2016;29:49–60.
 88. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, 
Segal E, Chang HY. Long noncoding RNA as modular scaffold of histone 
modification complexes. Science. 2010;329:689–93.
 89. Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene 
regulation, epigenetics and human disease. ChemMedChem. 
2014;9:1932–56.
 90. Kanduri C. Long noncoding RNA and epigenomics. Adv Exp Med Biol. 
2011;722:174–95.
 91. Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 
2012;338:1435–9.
 92. Wu Y, Zhang L, Wang Y, Li H, Ren X, Wei F, Yu W, Wang X, Yu J, Hao X. 
Long noncoding RNA HOTAIR involvement in cancer. Tumour Biol. 
2014;35:9531–8.
 93. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka 
F, Shibata K, Suzuki A, Komune S, et al. Long noncoding RNA HOTAIR 
regulates polycomb‑dependent chromatin modification and is 
associated with poor prognosis in colorectal cancers. Cancer Res. 
2011;71:6320–6.
 94. Li JT, Wang LF, Zhao YL, Yang T, Li W, Zhao J, Yu F, Wang L, Meng YL, Liu 
NN, et al. Nuclear factor of activated T cells 5 maintained by Hotair sup‑
pression of miR‑568 upregulates S100 calcium binding protein A4 to 
promote breast cancer metastasis. Breast Cancer Res. 2014;16:454.
 95. Vicent GP, Nacht AS, Zaurin R, Font‑Mateu J, Soronellas D, Le Dily 
F, Reyes D, Beato M. Unliganded progesterone receptor‑mediated 
targeting of an RNA‑containing repressive complex silences a subset of 
hormone‑inducible genes. Genes Dev. 2013;27:1179–97.
 96. Beato M, Vicent GP. A new role for an old player: steroid receptor RNA 
activator (SRA) represses hormone inducible genes. Transcription. 
2013;4:167–71.
 97. Porro A, Feuerhahn S, Lingner J. TERRA‑reinforced association of LSD1 
with MRE11 promotes processing of uncapped telomeres. Cell Rep. 
2014;6:765–76.
 98. Hay ED. An overview of epithelio‑mesenchymal transformation. Acta 
Anat (Basel). 1995;154:8–20.
 99. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial‑mesen‑
chymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.
 100. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial‑mesenchymal 
transitions in development and disease. Cell. 2009;139:871–90.
 101. Lin T, Ponn A, Hu X, Law BK, Lu J. Requirement of the histone demethyl‑
ase LSD1 in Snai1‑mediated transcriptional repression during epithelial‑
mesenchymal transition. Oncogene. 2010;29:4896–904.
 102. Lin Y, Dong C, Zhou BP. Epigenetic regulation of EMT: the Snail story. 
Curr Pharm Des. 2014;20:1698–705.
 103. Schildhaus HU, Riegel R, Hartmann W, Steiner S, Wardelmann E, 
Merkelbach‑Bruse S, Tanaka S, Sonobe H, Schule R, Buettner R, Kirfel 
J. Lysine‑specific demethylase 1 is highly expressed in solitary fibrous 
tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small 
round cell tumors, and malignant peripheral nerve sheath tumors. Hum 
Pathol. 2011;42:1667–75.
 104. Yu Y, Wang B, Zhang K, Lei Z, Guo Y, Xiao H, Wang J, Fan L, Lan C, Wei Y, 
et al. High expression of lysine‑specific demethylase 1 correlates with 
poor prognosis of patients with esophageal squamous cell carcinoma. 
Biochem Biophys Res Commun. 2013;437:192–8.
 105. Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE, Huang 
Y. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA 
methylation and increases sensitivity to DNMT inhibitor‑induced apop‑
tosis in breast cancer cells. Breast Cancer Res Treat. 2014;146:99–108.
 106. Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R, Helgason CD. The 
emerging role of histone lysine demethylases in prostate cancer. Mol 
Cancer. 2012;11:52.
 107. Urbanucci A, Waltering KK, Suikki HE, Helenius MA, Visakorpi T. Andro‑
gen regulation of the androgen receptor coregulators. BMC Cancer. 
2008;8:219.
 108. Suikki HE, Kujala PM, Tammela TL, van Weerden WM, Vessella RL, 
Visakorpi T. Genetic alterations and changes in expression of histone 
demethylases in prostate cancer. Prostate. 2010;70:889–98.
 109. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, 
Solleder G, Bastian PJ, Ellinger J, Metzger E, et al. Androgen receptor 
coactivators lysine‑specific histone demethylase 1 and four and a half 
LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer 
Res. 2006;66:11341–7.
 110. Metzger E, Willmann D, McMillan J, Forne I, Metzger P, Gerhardt S, 
Petroll K, von Maessenhausen A, Urban S, Schott AK, et al. Assembly of 
methylated KDM1A and CHD1 drives androgen receptor‑dependent 
transcription and translocation. Nat Struct Mol Biol. 2016;23:132–9.
 111. Wang M, Liu X, Jiang G, Chen H, Guo J, Weng X. Relationship between 
LSD1 expression and E‑cadherin expression in prostate cancer. Int Urol 
Nephrol. 2015;47:485–90.
 112. Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JL, 
Gudas LJ, Mongan NP. The lysine specific demethylase‑1 (LSD1/
KDM1A) regulates VEGF‑A expression in prostate cancer. Mol Oncol. 
2013;7:555–66.
 113. Maiques‑Diaz A, Somervaille TCP. Inhibit a kinase to degrade a histone 
demethylase: a candidate therapeutic approach in glioblastoma. Transl 
Cancer Res. 2017;6:S57–60.
Page 14 of 15Ismail et al. Epigenetics & Chromatin  (2018) 11:33 
 114. Rotili D, Tomassi S, Conte M, Benedetti R, Tortorici M, Ciossani G, Valente 
S, Marrocco B, Labella D, Novellino E, et al. Pan‑histone demethylase 
inhibitors simultaneously targeting Jumonji C and lysine‑specific dem‑
ethylases display high anticancer activities. J Med Chem. 2014;57:42–55.
 115. Scoumanne A, Chen X. The lysine‑specific demethylase 1 is required for 
cell proliferation in both p53‑dependent and ‑independent manners. J 
Biol Chem. 2007;282:15471–5.
 116. Ambrosio S, Amente S, Sacca CD, Capasso M, Calogero RA, Lania L, 
Majello B. LSD1 mediates MYCN control of epithelial‑mesenchymal 
transition through silencing of metastatic suppressor NDRG1 gene. 
Oncotarget. 2017;8:3854–69.
 117. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, 
Pajtler K, Klein‑Hitpass L, Kuhfittig‑Kulle S, et al. Lysine‑specific dem‑
ethylase 1 is strongly expressed in poorly differentiated neuroblastoma: 
implications for therapy. Cancer Res. 2009;69:2065–71.
 118. Althoff K, Beckers A, Odersky A, Mestdagh P, Koster J, Bray IM, Bryan K, 
Vandesompele J, Speleman F, Stallings RL, et al. MiR‑137 functions as a 
tumor suppressor in neuroblastoma by downregulating KDM1A. Int J 
Cancer. 2013;133:1064–73.
 119. Pajtler KW, Weingarten C, Thor T, Kunkele A, Heukamp LC, Buttner 
R, Suzuki T, Miyata N, Grotzer M, Rieb A, et al. The KDM1A histone 
demethylase is a promising new target for the epigenetic therapy of 
medulloblastoma. Acta Neuropathol Commun. 2013;1:19.
 120. Zhou A, Lin K, Zhang S, Chen Y, Zhang N, Xue J, Wang Z, Aldape KD, Xie 
K, Woodgett JR, Huang S. Nuclear GSK3beta promotes tumorigenesis 
by phosphorylating KDM1A and inducing its deubiquitylation by 
USP22. Nat Cell Biol. 2016;18:954–66.
 121. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA 
Cancer J Clin. 2014;64:52–62.
 122. Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A, Raza A. Breast 
cancer: major risk factors and recent developments in treatment. Asian 
Pac J Cancer Prev. 2014;15:3353–8.
 123. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how 
cellular identity goes awry. Dev Cell. 2010;19:698–711.
 124. Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, Kirfel J. 
Lysine‑specific demethylase 1 (LSD1) is highly expressed in ER‑negative 
breast cancers and a biomarker predicting aggressive biology. Carcino‑
genesis. 2010;31:512–20.
 125. Bradley C, van der Meer R, Roodi N, Yan H, Chandrasekharan MB, 
Sun ZW, Mernaugh RL, Parl FF. Carcinogen‑induced histone altera‑
tion in normal human mammary epithelial cells. Carcinogenesis. 
2007;28:2184–92.
 126. Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical 
spectrum. Endocr Rev. 1999;20:418–34.
 127. Pollock JA, Larrea MD, Jasper JS, McDonnell DP, McCafferty DG. 
Lysine‑specific histone demethylase 1 inhibitors control breast cancer 
proliferation in ERalpha‑dependent and ‑independent manners. ACS 
Chem Biol. 2012;7:1221–31.
 128. Kim J, Park U‑H, Moon M, Um S‑J, Kim E‑J. Negative regulation of ERα by 
a novel protein CAC1 through association with histone demethylase 
LSD1. FEBS Lett. 2013;587:17–22.
 129. Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y. 
Crosstalk between lysine‑specific demethylase 1 (LSD1) and histone 
deacetylases mediates antineoplastic efficacy of HDAC inhibitors in 
human breast cancer cells. Carcinogenesis. 2013;34:1196–207.
 130. Mosammaparast N, Kim H, Laurent B, Zhao Y, Lim HJ, Majid MC, 
Dango S, Luo Y, Hempel K, Sowa ME, et al. The histone demethyl‑
ase LSD1/KDM1A promotes the DNA damage response. J Cell Biol. 
2013;203:457–70.
 131. Wu Y, Wang Y, Yang XH, Kang T, Zhao Y, Wang C, Evers BM, Zhou BP. The 
deubiquitinase USP28 stabilizes LSD1 and confers stem‑cell‑like traits to 
breast cancer cells. Cell Rep. 2013;5:224–36.
 132. Feng J, Xu G, Liu J, Zhang N, Li L, Ji J, Zhang J, Zhang L, Wang G, Wang 
X, et al. Phosphorylation of LSD1 at Ser112 is crucial for its function in 
induction of EMT and metastasis in breast cancer. Breast Cancer Res 
Treat. 2016;159:443–56.
 133. Derr RS, van Hoesel AQ, Benard A, Goossens‑Beumer IJ, Sajet A, Dekker‑
Ensink NG, de Kruijf EM, Bastiaannet E, Smit VT, van de Velde CJ, Kuppen 
PJ. High nuclear expression levels of histone‑modifying enzymes LSD1, 
HDAC2 and SIRT1 in tumor cells correlate with decreased survival and 
increased relapse in breast cancer patients. BMC Cancer. 2014;14:604.
 134. Cao C, Vasilatos SN, Bhargava R, Fine JL, Oesterreich S, Davidson NE, 
Huang Y. Functional interaction of histone deacetylase 5 (HDAC5) and 
lysine‑specific demethylase 1 (LSD1) promotes breast cancer progres‑
sion. Oncogene. 2017;36:133–45.
 135. Chen L, Vasilatos SN, Qin Y, Katz TA, Cao C, Wu H, Tasdemir N, Levine KM, 
Oesterreich S, Davidson NE, Huang Y. Functional characterization of 
lysine‑specific demethylase 2 (LSD2/KDM1B) in breast cancer progres‑
sion. Oncotarget. 2017;8:81737–53.
 136. Yuan C, Li Z, Qi B, Zhang W, Cheng J, Wang Y. High expression of 
the histone demethylase LSD1 associates with cancer cell prolifera‑
tion and unfavorable prognosis in tongue cancer. J Oral Pathol Med. 
2015;44:159–65.
 137. Narayanan SP, Singh S, Gupta A, Yadav S, Singh SR, Shukla S. Integrated 
genomic analyses identify KDM1A’s role in cell proliferation via modu‑
lating E2F signaling activity and associate with poor clinical outcome in 
oral cancer. Cancer Lett. 2015;367:162–72.
 138. Wang Y, Zhu Y, Wang Q, Hu H, Li Z, Wang D, Zhang W, Qi B, Ye J, Wu H, 
et al. The histone demethylase LSD1 is a novel oncogene and therapeu‑
tic target in oral cancer. Cancer Lett. 2016;374:12–21.
 139. Ding J, Zhang ZM, Xia Y, Liao GQ, Pan Y, Liu S, Zhang Y, Yan ZS. LSD1‑
mediated epigenetic modification contributes to proliferation and 
metastasis of colon cancer. Br J Cancer. 2013;109:994–1003.
 140. Jie D, Zhongmin Z, Guoqing L, Sheng L, Yi Z, Jing W, Liang Z. Positive 
expression of LSD1 and negative expression of E‑cadherin correlate 
with metastasis and poor prognosis of colon cancer. Dig Dis Sci. 
2013;58:1581–9.
 141. Huang Z, Li S, Song W, Li X, Li Q, Zhang Z, Han Y, Zhang X, Miao S, Du 
R, Wang L. Lysine‑specific demethylase 1 (LSD1/KDM1A) contributes 
to colorectal tumorigenesis via activation of the Wnt/beta‑catenin 
pathway by down‑regulating Dickkopf‑1 (DKK1) [corrected]. PLoS ONE. 
2013;8:e70077.
 142. Hsu HC, Liu YS, Tseng KC, Yang TS, Yeh CY, You JF, Hung HY, Chen SJ, 
Chen HC. CBB1003, a lysine‑specific demethylase 1 inhibitor, sup‑
presses colorectal cancer cells growth through down‑regulation of 
leucine‑rich repeat‑containing G‑protein‑coupled receptor 5 expres‑
sion. J Cancer Res Clin Oncol. 2015;141:11–21.
 143. Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X, Song Y. Over‑expression of 
LSD1 promotes proliferation, migration and invasion in non‑small cell 
lung cancer. PLoS ONE. 2012;7:e35065.
 144. Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, 
Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, et al. A DNA 
hypomethylation signature predicts antitumor activity of LSD1 inhibi‑
tors in SCLC. Cancer Cell. 2015;28:57–69.
 145. Chen C, Ge J, Lu Q, Ping G, Yang C, Fang X. Expression of Lysine‑specific 
demethylase 1 in human epithelial ovarian cancer. J Ovarian Res. 
2015;8:28.
 146. Lan W, Zhang D, Jiang J. The roles of LSD1‑mediated epigenetic modi‑
fications in maintaining the pluripotency of bladder cancer stem cells. 
Med Hypotheses. 2013;81:823–5.
 147. Sakamoto A, Hino S, Nagaoka K, Anan K, Takase R, Matsumori H, Ojima 
H, Kanai Y, Arita K, Nakao M. Lysine demethylase LSD1 coordinates 
glycolytic and mitochondrial metabolism in hepatocellular carcinoma 
cells. Cancer Res. 2015;75:1445–56.
 148. Bennani‑Baiti IM, Machado I, Llombart‑Bosch A, Kovar H. Lysine‑specific 
demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an 
epigenetic drug target in chondrosarcoma, Ewing’s sarcoma, osteosar‑
coma, and rhabdomyosarcoma. Hum Pathol. 2012;43:1300–7.
 149. Kerenyi MA, Shao Z, Hsu YJ, Guo G, Luc S, O’Brien K, Fujiwara Y, Peng C, 
Nguyen M, Orkin SH. Histone demethylase Lsd1 represses hematopoi‑
etic stem and progenitor cell signatures during blood cell maturation. 
Elife. 2013;2:e00633.
 150. Sprussel A, Schulte JH, Weber S, Necke M, Handschke K, Thor T, Pajtler 
KW, Schramm A, Konig K, Diehl L, et al. Lysine‑specific demethylase 
1 restricts hematopoietic progenitor proliferation and is essential for 
terminal differentiation. Leukemia. 2012;26:2039–51.
 151. Vu LP, Luciani L, Nimer SD. Histone‑modifying enzymes: their role in the 
pathogenesis of acute leukemia and their therapeutic potential. Int J 
Hematol. 2013;97:198–209.
 152. Biswas D, Milne TA, Basrur V, Kim J, Elenitoba‑Johnson KS, Allis CD, 
Roeder RG. Function of leukemogenic mixed lineage leukemia 1 (MLL) 
Page 15 of 15Ismail et al. Epigenetics & Chromatin  (2018) 11:33 
fusion proteins through distinct partner protein complexes. Proc Natl 
Acad Sci U S A. 2011;108:15751–6.
 153. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser 
JG, Greystoke BF, Jordan AM, et al. The histone demethylase KDM1A 
sustains the oncogenic potential of MLL‑AF9 leukemia stem cells. 
Cancer Cell. 2012;21:473–87.
 154. Lokken Alyson A, Zeleznik‑Le Nancy J. Breaking the LSD1/KDM1A 
addiction: therapeutic targeting of the epigenetic modifier in AML. 
Cancer Cell. 2012;21:451–3.
 155. Feng Z, Yao Y, Zhou C, Chen F, Wu F, Wei L, Liu W, Dong S, Redell M, Mo 
Q, Song Y. Pharmacological inhibition of LSD1 for the treatment of MLL‑
rearranged leukemia. J Hematol Oncol. 2016;9:24.
 156. Mi JQ, Chen SJ, Zhou GB, Yan XJ, Chen Z. Synergistic targeted therapy 
for acute promyelocytic leukaemia: a model of translational research in 
human cancer. J Intern Med. 2015;278:627–42.
 157. Sanz MA, Lo‑Coco F. Modern approaches to treating acute promyelo‑
cytic leukemia. J Clin Oncol. 2011;29:495–503.
 158. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss 
D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist 
and pan‑histone deacetylase inhibitor against human AML cells. Leuke‑
mia. 2014;28:2155–64.
 159. Lopez CI, Saud KE, Aguilar R, Berndt FA, Canovas J, Montecino M, Kuku‑
ljan M. The chromatin modifying complex CoREST/LSD1 negatively 
regulates notch pathway during cerebral cortex development. Dev 
Neurobiol. 2016;76:1360–73.
 160. Yatim A, Benne C, Sobhian B, Laurent‑Chabalier S, Deas O, Judde JG, 
Lelievre JD, Levy Y, Benkirane M. NOTCH1 nuclear interactome reveals 
key regulators of its transcriptional activity and oncogenic function. 
Mol Cell. 2012;48:445–58.
 161. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor func‑
tions of Notch in cancer: it’s NOTCH what you think. J Exp Med. 
2011;208:1931–5.
 162. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone 
H3 lysine 4 demethylation is a target of nonselective antidepressive 
medications. Chem Biol. 2006;13:563–7.
 163. Schmidt DM, McCafferty DG. trans‑2‑Phenylcyclopropylamine is a 
mechanism‑based inactivator of the histone demethylase LSD1. Bio‑
chemistry. 2007;46:4408–16.
 164. Zheng YC, Ma J, Wang Z, Li J, Jiang B, Zhou W, Shi X, Wang X, Zhao W, 
Liu HM. A systematic review of histone lysine‑specific demethylase 1 
and its inhibitors. Med Res Rev. 2015;35:1032–71.
 165. Stazi G, Zwergel C, Valente S, Mai A. LSD1 inhibitors: a patent review 
(2010–2015). Expert Opin Ther Pat. 2016;26:565–80.
 166. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack‑
Sjodin PA, Allain CJ, Klaus CR, Raimondi A, Scott MP, et al. Potent 
inhibition of DOT1L as treatment of MLL‑fusion leukemia. Blood. 
2013;122:1017–25.
 167. Singh MM, Manton CA, Bhat KP, Tsai WW, Aldape K, Barton MC, Chandra 
J. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase 
inhibitors. Neuro Oncol. 2011;13:894–903.
 168. Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE. Inhibitors of his‑
tone demethylation and histone deacetylation cooperate in regulating 
gene expression and inhibiting growth in human breast cancer cells. 
Breast Cancer Res Treat. 2012;131:777–89.
 169. Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL. 
Mechanism and relevance of EWS/FLI‑mediated transcriptional repres‑
sion in Ewing sarcoma. Oncogene. 2016;35:6155–6.
 170. Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U, Ma H, Chen 
L, Venkannagari S, Ha K, et al. Targeting levels or oligomerization of 
nucleophosmin 1 induces differentiation and loss of survival of human 
AML cells with mutant NPM1. Blood. 2011;118:3096–106.
 171. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, 
Sondarva G, Moscinski L, Atadja P, Bhalla K. Combination of the histone 
deacetylase inhibitor LBH589 and the hsp90 inhibitor 17‑AAG is highly 
active against human CML‑BC cells and AML cells with activating muta‑
tion of FLT‑3. Blood. 2005;105:1768–76.
 172. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao 
R, Fernandez P, Chen J, et al. Combined epigenetic therapy with the 
histone methyltransferase EZH2 inhibitor 3‑deazaneplanocin A and the 
histone deacetylase inhibitor panobinostat against human AML cells. 
Blood. 2009;114:2733–43.
 173. Robertson JC, Hurley NC, Tortorici M, Ciossani G, Borrello MT, Vellore 
NA, Ganesan A, Mattevi A, Baron R. Expanding the druggable space of 
the LSD1/CoREST epigenetic target: new potential binding regions for 
drug‑like molecules, peptides, protein partners, and chromatin. PLoS 
Comput Biol. 2013;9:e1003158.
